Videos and programmes from past forums are archived here in the hope that they will be a useful resource.
Select the year that you’re interested in, to see the details of the forums that were held that year.
Asian Virtual 2021
Programmes
Asian Retina – Panel sessions
- Panel 1: Is Myopia prevention a viable business opportunity?
- Panel 2: Real world anti-VEGF utilisation in Asia and the opportunity for Gene Therapy
- Panel 3: Investment update & panel discussion
- Panel 4: Access to modern retina surgery in Asia: Is it improving?
- Panel 5: Innovation in imaging and telemedicine to improve remote access to ophthalmic care
- Panel 6: Reducing the unmet need for care in Asia: Surgical robotics & smart implants
Asian Retina – Company presentations
- Adverum Biotechnologies
Aaron Osborne | CMO - AsclepiX Therapeutics, Inc.
Theresa Heah | CMO - AVECRIS Pte Ltd.
Volker Patzel | Founder - GenSight Biologics
Magali Taiel | CMO - Isarna Therapeutics
Marion Munk | CEO - Iveric Bio
Pravin Dugel | CBO - Norlase
Oliver Hvidt | CEO - Notal Vision Inc.
Kester Nahen | CEO - NovaSight
Ran Yam | CEO - Ocuphire Pharma
Mina Sooch | CEO - OcuTerra Therapeutics
Kerrie Brady | CEO - Preceyes
Marc De Smet | CMO - RE-VANA THERAPEUTICS
Michael O’Rourke | CEO - Risk Medical Solutions
Sigurbjörg Ásta Jónsdóttir | CEO - Samsara Vision
Thomas Ruggia | CEO
Asian – Panel sessions
- An Interview with Shigeo Taniuchi, President and CEO, Santen Pharmaceutical Co. Ltd
- A Market Overview, Seth Samergy
- Panel 1: Will ICLs bring a SMILE to refractive surgeons in Asia?
- Panel 2: How will corneal endothelial transplantation change eye bank cost and revenue models?
- Panel 3: Can Asia reverse the global femto bust?
- Panel 4: An Asian Leadership Perspective – How has business changed after COVID?
- Panel 5: Investment opportunities in ophthalmology in Asia
- Panel 6: Navigating IP management challenges in Asia
- Panel 7: Cost and quality in meeting the cataract backlog: private vs public sector approaches
- Panel 8: MIGS for angle closure: The next horizon?
Asian – Company presentations
- 2Eyes Vision S.L
Susana Marcos | Co-founder - Avellino Labs
Eric Bernabei| Global Head of Corporate & Business Development - BELKIN Laser
Daria Lemann-Blumenthal | CEO - BioLight Life Sciences Ltd.
Yaacov Michlin | CEO - CorNeat Vision
Almog Aley-Raz | CEO - Equinox Ophthalmic, Inc.
John Berdahl | CMO - EYE TECH CARE
Dietrich Wolf| CEO - Eye-Yon Medical
Nahum Ferera | CEO - LENSAR, Inc.
Nick Curtis| CEO - LensGen
Sumit Garg | Medical Director - Medtechnoskorp Ltd.
Rupert Mok | CEO - Photon Therapeutics Ltd.
Sunil Shah | Consultant Ophthalmologist - Pleryon Therapeutics
Yu Yu | CEO - Premark Pharma
Ian Vessey | Managing Director - Radiance Therapeutics
Abigail Mackrill | Director of Business Development - TECLens, LLC
Patrick Lopath | COO - Wolfcreek Biotech Pte Ltd.
Cherry Khoo | Managing Director
Virtual 2020
Programmes
Retina – Panel sessions
- Panel 1: Can AI Help Us Beyond Retinal Imaging?
- Panel 2: Anti-VEGF Drugs for Retinal Disease: Is There Room for More?
- A One to One with Marie-France Tschudin, President of Novartis Pharmaceuticals
- Panel 3: Gene and Cell-based Therapy for Retinal Disease: Opportunities and Challenges
- Investment Overview with Naveed Siddiqi
- Panel 4: The Dream Vs the Reality: Making Investments in Retina, an Investor Perspective
- Panel 5: Surgical Instrumentation and Microscopy: A Real Business or a Revenue Rounding Error
- Panel 6: Novel Drug Delivery Approaches for Posterior Segment Disease
- A fireside chat with Dr. Wiley Chambers, USFDA
- Panel 7: The Impact of COVID-19 on Retina Discovery, Development and Business
Retina – Company presentations
- Adverum Biotechnologies
Aaron Osborne | CMO - Aerie Pharmaceuticals, Inc.
Casey Kopczynski | CSO - Apellis
Ramiro Ribeiro | Sr. Medical Director - Clearside Biomedical
Thomas Ciulla | CMO - Eyevensys
Ronald Buggage | CMO - ForwardVue Pharma
Alan Franklin | Founder - GenSight Biologics
Magali Taiel | CMO - Graybug Vision
Fred Guerard | CEO - Imagine Eyes
Nicolas Chateau | CEO - IVERIC bio
Kourous Rezaei | CMO - Kodiak Sciences, Inc.
Jason Ehrlich | CMO & CDO - Macuject Pty Ltd.
Devinder Chauhan | CEO - Neurotech Pharmaceuticals, Inc.
Rich Small | CEO - Notal Vision, Inc.
Kester Nahen | CEO - Oculis S.A.
Marcia de Souza Lima | CMO - Preceyes BV
Gerrit Naus | CEO & Co-founder - ProQR Therapeutics
Aniz Girach | CMO - Re-Vana Therapeutics
Michael O’Rourke | CEO - REGENXBIO
Steve Pakola | CMO - ReNeuron
Rick Beckman | CMO - RetinaRisk
Einar Stefánsson | Founder
European – Panel sessions
- Panel 1: The Global Dry Eye Opportunity: Will it Ever be Realised?
- Panel 2: Big idea and No Money: Who Do I Call in a Big Company?
- Leadership Perspective with Shigeo Taniuchi
- Panel 3: Drug Delivery for Eye Diseases: Simply Cool Technology or also a Commercial Success?
- Panel 4: Cataract and Other Elective Surgery in the Era of COVID-19
- Panel 5: Refractive Outcomes after Cataract Surgery: IOL Adjustment Vs Enhancement
- Panel 6: Premium IOL Patient-reported Outcomes and Regulatory Processes
- Panel 7: Will Endothelial Damage Restrict Glaucoma Device Progression?
- Panel 8: Opportunities in Ophthalmology – Investors’ Perspective
- Panel 9: Femto a Decade Later: Was it Worth the Investment?
- A View from the Top: The Long-term Impact of COVID-19 on the Business of Ophthalmology
European – Company presentations
- 2EyesVision
Susana Marcos | Co-founder - AcuFocus
Yari Mitchell | Chief Business Development Officer - Aerie Pharmaceuticals
Michelle Senchyna | Vice President - Avellino
Eric Bernabei | Chief Sales & Marketing Officer - Azalea Vision
Enrique Vega | CEO - Belkin Laser
Daria Leann-Blumenthal | CEO - Centricity Vision
Rob Thornhill | CEO - EyeYon Medical
Nahum Ferera | CEO & CO-founder - Implandata Ophthalmic Products
Max Ostermeier | CEO - Intelon Optics
Dimitri Chernyak | CEO - Isarna Therapeutics
Marion Munk | CMO - iStar Medical
Michel Vanbrabant | Vice President - Kali Care
Sina Fateh | CEO - LENSAR, Inc.
Nick Curtis | CEO - LensGen
Sumit Garg | Scientific Advisor - Liqid Medical
Daemon McClunan | Founder & CEO - NovaSight
Ran Yam | CEO - Oculis S.A.
Marcia de Souza Lima | CMO - Photon Therapeutics
Sunil Shah | Consultant Ophthalmologist - Rheon Medical
Nikos Stergiopulos | CEO - Samsara Vision, Inc.
Thomas Ruggia | President & CEO - Sanoculis
Nir Israeli | CEO - Sight Sciences
Patrick Smale | Vice President - TearClear
Robert Dempsey | CEO - Voptica
Pablo Artal | Professor
Paris 2019
Programmes
Retina – Panel sessions
- Endpoints for Macular Therapeutic Trails: Is it all about Vision or should Anatomy Matter?
- Is Retina Overheated for Investors?
- Machine Learning and Artificial Intelligence: Added Value or Passing Fad?
- Novel Pharmaceutical Agents and Delivery
- Perspective by Nanna Luneborg
- Retina Innovation in the 2020s
- Safety, Vectors and Routes of Delivery for Stem Cells and Gene Therapy
- The Role of OCT Angiography and Other Image Device
- Vitreo-Retinal Surgery and Robotics
Retina – Company presentations
- Aerie
- Apellis
- Eyevensis
- Galimedix
- GenSight
- Graybug
- Gyroscope
- HORAMA
- Imagine Eyes
- Iveric Bio
- Kodak Science
- MMI
- Oxurion
- Preceyes
- Re-Vana Therapeutics
- RegenXBio
- ReNeuron
- Retina Risk
European – Panel sessions
- A View From the Top: What Keeps the Big Company Leaders up at Night?
- Can Big Data and Artificial Intelligence Help Product Development?
- Cataract Technology: Can Simpler and Cheaper Actually be Better?
- Corneal vs Lens-based Refractive Surgical and Non-Surgical Options for Presbyopia
- Glaucoma Drug Delivery: Why is it Taking So Long?
- IOL Technology: Adjustable Intraocular Lenses Versus Getting it Right the First Time?
- Market Overview by Michael Giaquinto
- Shark Tank
- The MIGS Era: The Beginning of the End or the End of the Beginning?
- The Impact of Economic Cycles on Biotech and Medtech Funding?
- Will Device Based Dry Eye Therapy Challenge Drugs?
- Why No Startup Should Bank on Milestone Payments
European – Company presentations
Vienna 2018
Programmes
Retina – Panel sessions
- Artificial Intelligence?
- Fewer Injections Better Outcomes with Anti VEGF: Can You Have Your Cake and Eat It?
- Gene Replacements Vs Protein Therapy for Retinal Disease: Targets, Challenges and Business Strategies
- Microinstrumental for Vitreoretinal surgery: Is It All About Size?
- Why is Retina so Exciting to Investors?
Retina – Company presentations
European – Panel sessions
- A View From the Top – Corporate CEO’s Interviewed
- Drug Delivery for Glaucoma: Pending Reality or Passing Fantasy
- Innovation Pipeline
- Market Overview – Investing in Ophthalmology
- Novel Pharmaceutical Therapies for Presbyopia, Cataract and Other Forms of Ageing
- Shark Tank
- The Quality-Efficiency Tradeoff in Modern Cataract Surgery Technology
- Will any New IOL Tech Company remain unsold?
- Will Bleb Formation Divide the MIGS Market
- Will the Evolving Economic Landscape for Dry Eye Products Impact Investment
European – Company presentations
- Aerie Pharmaceuticals
- EyeTech Care
- Eyeon Medical
- Infinite Vision Optics
- iStar Medical SA
- Keranova
- LensGen
- Mynosys
- Novaliq GmbH
- Ocular Therapeutix
- Panotopes Pharma
- Re-Vana Therapeutics
- Refocus
- Rheon Medical SA
- Sanoculis
- Voptica
Hong Kong 2018
Programme
Panel sessions
- A View from Global Corporate Leaders
- Guest of Honour – Prof. Anthony Wu
- How Will the Glaucoma Device Boom Affect Asia?
- Ophthalmic Innovation Case Study: C-Mer Holdings
- Presbyopia and Cataracts: Femto, Eyedrops and Accommodating IOL’s
- Skynet and the Eye: Retinal Imaging and Artificial Intelligence
- The Changing Healthcare Market in Asia
- The Changing Market for Refractive Surgery
- The Myopia Epidemic: Opportunities and Potential Solutions
- The Regulatory Pathways in China
- What are the Prospects for the Ocular Surface?
- Will New Modes of Glaucoma Drug Delivery Eclipse the Device Boom?
- Wooing Asian Investors
Company presentations
Lisbon 2017
Programme
Panel sessions
- A view from the top: Corporate CEOs interviewed
- Dry AMD: Current challenges and future trends
- Dry eye: Will there be any in the house?
- MIGS and glaucoma drug delivery: Will European reimbursement drain enthusiasm?
- Pearls for innovation
- Perspectives from top venture capitalists
- Presbyopia: More than just Lenses?
- Shark Tank
- Who should you talk to in order to sell your company?
- Will refractive surgery bring a SMILE to Lasik surgeons?
Company presentations
- AcuFocus
- Camras Vision
- EyeYon Medical
- Implandata
- Innfocus
- Kali Care
- Medicem
- Mupharma
- Mynosys Cellular Devices
- OptoLight Vision
- Presbia
- Re-Vana Therapeutics
- Refocus
- Rheon Medical
- Sensimed
- SRD Vision
- TearLab
- Vivior AG
- Z Lens
Singapore 2017
Programme
Forum overview
Panel sessions
- A view from the top – Keith Barton interviews Flemming Ornskov, Chief Executive Officer, Shire Plc., USA
- Session 1 – Beyond anti-VEGFs- surviving the injections
- Session 2 – Developing and taking a new idea to market
- Session 3 – The Asian investment climate
- Session 4 – Trends in glaucoma devices and drug delivery in Asia – The buyers’ aspirations and the sellers
- Session 5 – Market access for femtosecond laser cataract surgery and premium IOLs in Asia
- Session 6 – The future of anti-microbials – enough of our -cins
- Session 7 – Will laser refractive surgery bring a smile to Asian ophthalmologists
- Session 8 – A view from the top – Ophthalmic innovation
Company presentations
- Abyss Processing Ptd. Ltd. – Michael Girard, Assistant Professor, National University of Singapore
- Ace Vision Group, Inc. – AnnMarie Hipsley, Chief Executive Officer, Ace Vision Group, Inc.
- Avacta Life Sciences – Amrik Basran, Chief Scientific Officer, Avacta Life Sciences
- Cassini B.V – Tom Dunlap, Chairman, Cassini B.V
- Ellex Medical Lasers – Tom Spurling, Chief Executive Officer, Ellex Medical Lasers
- Eye Tech Care – Dietrich Wolf, Chief Executive Officer, Eye Tech Care
- Guangzhou Biotechnology Company – Rajvardhan Azad, Consultant Viteroretinal Surgeon and ROP Specialist, Bharti Eye Hospital
- HE Innovation Centre – Wei He, President, HE University Eye Hospital
- InfiniteVision Optics SAS – Carsten Laue, Chief Executive Officer, InfiniteVision Optics SAS
- Ivantis Inc. – Glen Burgess, Managing Director Asia-Pacific, Ivantis Inc.
- OccuRx – Darren Kelly, Chief Executive Officer, OccuRx
- pH Pharma Co. Ltd. – Sanjeev Satyal, Vice President, pH Pharma Co. Ltd.
- SinSa Labs – Roger Beuerman Chief Financial Officer, SinSa Labs
- Z Lens LLC – Paul Marius Beer, Chief Executive Officer, Z Lens LLC
Copenhagen 2016
Programme
Forum overview
Panel sessions
- Shark Tank
- Panel 1 – AMD Is The Pipeline Dry?
- Panel 2 – Why is gene therapy not yet in the DNA of Big Pharma 2016
- Panel 3 – Imaging: OCT Angiography
- Panel 4 – Trifocal and Extended Depth of Focus 2016
- Panel 5 – Leading Venture Capitalists
- Panel 6 – Dry Eye: Will New Science Lubricate the Market 2016
- Panel 8 – Capsule-centred IOLs
- Panel 9 – A View From The Top: Corporate CEOs
Company presentations
- Apellis – Cedric Francois
- Salutaris Medical Devices – Laurence Marsteller
- Cassini – Jeroen Cameraat
- Kali Care – Sina Fateh
- Aerie Pharmaceuticals – John Thygesen
- NightstaRx – David Fellows
- Q&A session 1
- Intelon Optics – Dominik Beck
- Allotex – Michael Mrochen
- EyeYon Medical – Nahum Ferera
- Altacor – Francesca Crawford
- Mynosys Inc – John N Hendrick
- Z Lens LLC – Paul Beer
- Lens Gen – Ramgopal Rao
- AcuFocus – Nicholas Tarantino
- Q&A session 2
- ALeyeGN Technologies LLC – Michael Ballard
- Innfocus – Russ Trenary
- Ivantis Hydrus – Dave Van Meter
- AQ BioMed Futures – Jim Kasic
- Intelon Presentation
Barcelona 2015
Programme
Forum overview
Panel sessions
- Buyers & Sellers: A View From The Top
- Does Minimally Invasive Glaucoma Surgery Address A True Unmet Need?
- Opthalmic Pharma Innovation: Will The Breakthroughs Come In-house Or Via Acquisition?
Company presentations
Tokyo 2014
Programme
Panel sessions
- The role of global ophthalmic organisations in promulgating technological innovation
- Emerging needs and opportunities for industry in meeting eye care needs of low and middle income countries
- How will patient expectations drive corneal and refractive surgical innovation?
- Understanding ophthalmic product regulation around the globe: the best way to promote innovation
- Disruptive cataract surgery innovation: will outcomes drive reimbursement?
- Perspective: Innovation in EHRs
- Perspectives: Opensource Solutions: Openeyes
- Future pharmaceutical innovation: New molecules versus improved drug delivery
- Ophthalmic investment and innovation: East meets West
- Grow, partner or exit? A globalized question
London 2014
Programme
Opening sessions
- Opening Remarks – Keith Barton and Kuldev Singh
- Insight – Gaps in the Market – Anterior Segment
- Insight – Gaps in the Market – Posterior Segment
- Shark Tank
Panel sessions
- Gene therapy and Stem Cells
- Barriers to More Precise Outcomes
- Reimbursement for Novel Cataract Surgery
- Placing Multile Bets
- Innovation Cycle
- Pyschotherapy
- Therapeutic Pipeline
- The Next Generation of Ophthalmic Imaging Devices
- RIP
- Best Practices
Company presentations
- Anterior – Forsight
- Anterior – Acufocus
- Anterior – Wavetec
- Anterior – iOptics
- Anterior – Akkolens
- Anterior – Medicem
- Anterior – Camras
- Anterior – Mimetogen
- Anterior – DSM
- Anterior – Medicontur
- Posterior – Hemera
- Posterior – Graybug
- Posterior – OD-OS
- Posterior – Salutaris
- Posterior – Oraya
